KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Non Operating Income (2021 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Non Operating Income for 3 consecutive years, with -$33.8 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Non Operating Income fell 177.01% year-over-year to -$33.8 million, compared with a TTM value of -$28.5 million through Dec 2023, down 132.59%, and an annual FY2025 reading of $1.7 million, down 86.3% over the prior year.
  • Non Operating Income was -$33.8 million for Q4 2023 at Ginkgo Bioworks Holdings, down from -$16.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $82.6 million in Q1 2022 and bottomed at -$75.9 million in Q3 2021.
  • Average Non Operating Income over 3 years is $4.1 million, with a median of -$5.5 million recorded in 2021.
  • Peak annual rise in Non Operating Income hit 563.44% in 2022, while the deepest fall reached 552.2% in 2022.
  • Year by year, Non Operating Income stood at $79.1 million in 2021, then tumbled by 44.52% to $43.9 million in 2022, then crashed by 177.01% to -$33.8 million in 2023.
  • Business Quant data shows Non Operating Income for DNA at -$33.8 million in Q4 2023, -$16.5 million in Q3 2023, and $10.9 million in Q2 2023.